CA2251972A1 - Therapie combinatoire pour reduire les risques associes a une maladie cardiovasculaire - Google Patents
Therapie combinatoire pour reduire les risques associes a une maladie cardiovasculaire Download PDFInfo
- Publication number
- CA2251972A1 CA2251972A1 CA002251972A CA2251972A CA2251972A1 CA 2251972 A1 CA2251972 A1 CA 2251972A1 CA 002251972 A CA002251972 A CA 002251972A CA 2251972 A CA2251972 A CA 2251972A CA 2251972 A1 CA2251972 A1 CA 2251972A1
- Authority
- CA
- Canada
- Prior art keywords
- hmg
- inhibitor
- pharmaceutically acceptable
- vitamin
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention présente des méthodes tant pour prévenir ou réduire le risque de contracter l'athérosclérose, que pour enrayer cette maladie ou ralentir sa progression une fois qu'elle est devenue cliniquement évidente; elles consistent à administrer une quantité thérapeutique d'un HMG-CoA RI en combinaison avec l'acide folique ou encore un de ses sels ou esters pharmacocompatibles, à une personne qui risque de contracter l'athérosclérose ou qui est déjà atteinte.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1568996P | 1996-04-17 | 1996-04-17 | |
US60/015,689 | 1996-04-17 | ||
GB9612082.9 | 1996-06-10 | ||
GBGB9612082.9A GB9612082D0 (en) | 1996-06-10 | 1996-06-10 | Combination therapy for reducing the risks associated with cardiovascular disease |
US2097796P | 1996-06-24 | 1996-06-24 | |
US60/020,977 | 1996-06-24 | ||
GB9616804.2 | 1996-08-09 | ||
GBGB9616804.2A GB9616804D0 (en) | 1996-08-09 | 1996-08-09 | Combination therapy for reducing the risks associated with cardiovascular disease |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2251972A1 true CA2251972A1 (fr) | 1997-10-23 |
Family
ID=27451457
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002251972A Abandoned CA2251972A1 (fr) | 1996-04-17 | 1997-04-14 | Therapie combinatoire pour reduire les risques associes a une maladie cardiovasculaire |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0904082A4 (fr) |
JP (1) | JP2000508659A (fr) |
AU (1) | AU732465B2 (fr) |
CA (1) | CA2251972A1 (fr) |
WO (1) | WO1997038694A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0946178A4 (fr) * | 1996-09-18 | 2003-05-07 | Merck & Co Inc | Traitement combine destine a reduire les risques de maladies cardio-vasculaires |
AU9454098A (en) * | 1997-09-24 | 1999-04-12 | Nova Molecular, Inc. | Methods for increasing apoe levels for the treatment of neurodegenerative disease |
AU1306099A (en) * | 1997-12-12 | 1999-07-05 | Warner-Lambert Company | Antihyperlipidemic statin-lp(a) inhibitor combinations |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
GB2336534A (en) * | 1998-04-24 | 1999-10-27 | Alec James Coppen | Anti-depressant - Folic Acid Combination |
AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
AU4671101A (en) * | 2000-04-10 | 2001-10-23 | Malcolm R. Law | Formulation for the prevention of cardiovascular disease |
GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
US6916849B2 (en) | 2000-10-23 | 2005-07-12 | Sankyo Company, Limited | Compositions for improving lipid content in the blood |
CN1250212C (zh) * | 2000-10-23 | 2006-04-12 | 三共株式会社 | 血中脂类改善剂组合物 |
CA2428204A1 (fr) | 2000-11-07 | 2002-05-16 | Sankyo Company, Limited | Compositions permettant de reduire la concentration de peroxydes lipidiques |
MXPA03004818A (es) * | 2000-11-29 | 2003-09-10 | Smithkline Beecham Corp | Composicion conteniendo estatinas y calcio para salud cardiovascular mejorada. |
US7037934B2 (en) | 2000-12-14 | 2006-05-02 | Sankyo Company, Limited | Blood lipid ameliorant composition |
WO2002047683A1 (fr) * | 2000-12-14 | 2002-06-20 | Sankyo Company, Limited | Composition ameliorant les lipides dans le sang |
WO2002047682A1 (fr) * | 2000-12-14 | 2002-06-20 | Sankyo Company, Limited | Composition ameliorant les lipides sanguins |
TWI284529B (en) * | 2000-12-18 | 2007-08-01 | Sankyo Co | A composition for lowering triglyceride |
PT1413331E (pt) * | 2001-01-26 | 2007-12-18 | Schering Corp | Combinações do activador do receptor activado por proliferador do peroxisoma (ppar) fenofibrato e inibidor da absorção de esterol para indicações vasculares. |
JP4611622B2 (ja) * | 2002-07-11 | 2011-01-12 | 第一三共株式会社 | 血中脂質改善又は血中ホモシステイン低下のための医薬組成物 |
WO2004006919A1 (fr) * | 2002-07-11 | 2004-01-22 | Sankyo Company, Limited | Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine |
AR040588A1 (es) | 2002-07-26 | 2005-04-13 | Schering Corp | Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa |
JP4607436B2 (ja) * | 2002-08-02 | 2011-01-05 | 第一三共株式会社 | HMG−CoAリダクターゼ阻害剤を含有する医薬組成物 |
WO2004012740A1 (fr) * | 2002-08-02 | 2004-02-12 | Sankyo Company, Limited | Composition medicamenteuse contenant un inhibiteur de hmg-coa reductase |
US20070280915A1 (en) * | 2003-12-23 | 2007-12-06 | Medicure International Inc. | Combination Therapies Employing A Composition Comprising A Hmg Coa Reductase Inhibitor And A Vitamin B6 Related Compound |
CA2794424C (fr) * | 2004-03-29 | 2019-06-04 | Wyeth Llc | Complements nutritionnels mineraux multivitamines |
EP1841436A4 (fr) * | 2005-01-05 | 2008-02-20 | Medicure Int Inc | Composes et techniques de regulation des niveaux de triglyceride |
AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
EP2810644A1 (fr) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Formulation orale pour le traitement de maladies cardiovasculaires |
JP6443935B2 (ja) * | 2013-07-26 | 2018-12-26 | 学校法人 久留米大学 | 動脈硬化の治療または予防のためのアスピリンおよび葉酸の併用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3895107A (en) * | 1970-04-15 | 1975-07-15 | Morrison L M | CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals |
US5084482A (en) * | 1990-04-10 | 1992-01-28 | The Lithox Corporation | Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds |
DE4326698C2 (de) * | 1993-08-09 | 1997-05-28 | Puetter Medice Chem Pharm | Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Prophylaxe und Therapie von Arteriosklerose |
US5631401A (en) * | 1994-02-09 | 1997-05-20 | Abbott Laboratories | Inhibitors of protein farnesyltransferase and squalene synthase |
-
1997
- 1997-04-14 AU AU26665/97A patent/AU732465B2/en not_active Ceased
- 1997-04-14 JP JP9537264A patent/JP2000508659A/ja not_active Ceased
- 1997-04-14 CA CA002251972A patent/CA2251972A1/fr not_active Abandoned
- 1997-04-14 WO PCT/US1997/006127 patent/WO1997038694A1/fr not_active Application Discontinuation
- 1997-04-14 EP EP97918595A patent/EP0904082A4/fr not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0904082A1 (fr) | 1999-03-31 |
WO1997038694A1 (fr) | 1997-10-23 |
EP0904082A4 (fr) | 2001-09-26 |
JP2000508659A (ja) | 2000-07-11 |
AU732465B2 (en) | 2001-04-26 |
AU2666597A (en) | 1997-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2251972A1 (fr) | Therapie combinatoire pour reduire les risques associes a une maladie cardiovasculaire | |
US6673831B1 (en) | Combination therapy for reducing the risks associated with cardiovascular disease | |
US6245797B1 (en) | Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease | |
JP4711600B2 (ja) | シトステロール血症の処置のための置換アゼチジノン化合物の使用 | |
ES2342609T3 (es) | Agente terapeutico para hiperlipemia que comprende pitavastatinas y acido eicosapentaenoico. | |
Bermingham et al. | Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil | |
AU753657B2 (en) | Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease | |
CA2039763A1 (fr) | Combinaison de provastatine et d'un derive de l'acide fibrique, et mode de traitement de la dyslipidemie a l'aide de cette combinaison | |
EP0373507A1 (fr) | Combinaison d'un inhibiteur de HMG-CoA réductase et autres agents réduisant le cholestérol du sérum et méthode pour diminuer le cholestérol du sérum utilisant celle combinaison | |
EP0475148A1 (fr) | Pravastatine seule ou en combinaison avec un dérivé de l'acide fibrique pour prévenir l'apparition ou traiter l'hyperlipoprotéinémie de type III | |
WO1999017612A1 (fr) | Procede d'elaboration d'une preparation orale contenant de la serotonine, et methodes d'utilisation associees | |
WO2001045698A1 (fr) | Therapie combinee pour le traitement de maladie neurodegenerative | |
US4559326A (en) | Antiinflammatory compositions and methods | |
JPH0140009B2 (fr) | ||
US6890941B1 (en) | Compositions containing HMG Co-A reductase inhibitors and policosanol | |
US4534974A (en) | Pharmaceutical compositions with codeine | |
US20040023919A1 (en) | Blood lipid ameliorant composition | |
CN100566716C (zh) | 治疗高血脂症的组合物 | |
WO1998001116A1 (fr) | Therapie contre l'hyperlipemie combinee | |
WO2001085155A1 (fr) | Procede et compositions pour l'inhibition de l'arteriosclerose | |
AU6219799A (en) | Pharmaceutical combination of ibuprofen-lysine and domperidone for treating migraine | |
CN100358526C (zh) | 治疗高血脂症的组合物 | |
Randinitis et al. | Pharmacokinetic profile of a 300‐mg extended phenytoin sodium capsule (Dilantin) formulation | |
JP2003501385A (ja) | Hmg−coaレダクターゼ阻害剤とカルニチン類を含む抗高脂血症性組合せ | |
CN1332657C (zh) | 一种含洛伐他汀的组合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |